Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Phase 2

Recruiting

Conditions: PCNSL

Interventions: Drug: Rituximab
Drug: Lenalidomide
Drug: Methotrexate

First Posted Date: 2020-07-22

Last Posted Date: 2022-11-08

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 240

Registration Number: NCT04481815

Locations: 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Phase 1

Active, not recruiting

Conditions: Cutaneous T-Cell Lymphoma
Mature T-cell Malignancies
Peripheral T-Cell Lymphoma
Relapsed/ Refractory T-cell Malignancies

Interventions: Drug: Romidepsin
Drug: Lenalidomide
Drug: CC-486 (5-azacitidine)
Drug: Dexamethasone

First Posted Date: 2020-06-25

Last Posted Date: 2024-07-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT04447027

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Phase 1

Recruiting

Conditions: Refractory Marginal Zone Lymphoma
Recurrent Indolent Adult Non-Hodgkin Lymphoma
Recurrent Follicular Lymphoma
Recurrent Marginal Zone Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Follicular Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
Refractory Indolent Adult Non-Hodgkin Lymphoma

Interventions: Drug: Venetoclax
Drug: Lenalidomide
Biological: Rituximab
Biological: Rituximab and Hyaluronidase Human

First Posted Date: 2020-06-25

Last Posted Date: 2024-06-10

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 30

Registration Number: NCT04447716

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)

Phase 1

Recruiting

Conditions: Lymphoma, Large B-Cell, Diffuse
Central Nervous System Neoplasms, Primary

Interventions: Drug: Lenalidomide
Drug: Ibrutinib

First Posted Date: 2020-06-25

Last Posted Date: 2024-07-29

Lead Sponsor: Institut Curie

Target Recruit Count: 118

Registration Number: NCT04446962

Locations: 🇫🇷
CHU Besançon, Besançon, France
🇫🇷
CHU Amiens, Amiens, France
🇫🇷
CHU Angers, Angers, France

and more 26 locations

Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas

Conditions: Non-hodgkin Lymphoma,B Cell

Interventions: Drug: Lenalidomide

First Posted Date: 2020-06-17

Last Posted Date: 2020-07-07

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 1000

Registration Number: NCT04435743

Locations: 🇨🇳
Shanghai Ruijin Hospital, Shanghai, China

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1

Completed

Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Interventions: Drug: Zanubrutinib
Drug: Lenalidomide

First Posted Date: 2020-06-17

Last Posted Date: 2024-12-18

Lead Sponsor: BeiGene

Target Recruit Count: 66

Registration Number: NCT04436107

Locations: 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

and more 7 locations

Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

Not Applicable

Recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Lenalidomide

First Posted Date: 2020-06-16

Last Posted Date: 2020-06-16

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 124

Registration Number: NCT04432402

Locations: 🇨🇳
The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), Nanjing, Jiangsu, China

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

Phase 1

Recruiting

Conditions: Untreated
DLBCL
MYC Gene Rearrangement

Interventions: Drug: Lenalidomide
Drug: Rituximab
Drug: Etoposide
Drug: Doxorubicin
Drug: Vincristine
Drug: Cyclophosphamide
Drug: Prednisone

First Posted Date: 2020-06-16

Last Posted Date: 2020-06-16

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 81

Registration Number: NCT04432714

Locations: 🇨🇳
The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), Nanjing, Jiangsu, China

KRDI in Transplant-Eligible MM

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Isatuximab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2020-06-12

Last Posted Date: 2024-12-06

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 50

Registration Number: NCT04430894

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

Phase 1

Recruiting

Conditions: PTCL, NOS
AITL
ALK- ALCL
Phase III-IV ALK+ ALCL
EATL

Interventions: Drug: Lenalidomide
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisolone

First Posted Date: 2020-06-09

Last Posted Date: 2020-06-16

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 91

Registration Number: NCT04423926

Locations: 🇨🇳
The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), Nanjing, Jiangsu, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy